Checkpoint Therapeutics Stock Buy Hold or Sell Recommendation
| CKPT Stock | USD 3.97 0.02 0.50% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Checkpoint Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Checkpoint Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Checkpoint Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Checkpoint Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide. Note, we conduct extensive research on individual companies such as Checkpoint and provide practical buy, sell, or hold advice based on investors' constraints. Checkpoint Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Checkpoint |
Execute Checkpoint Therapeutics Buy or Sell Advice
The Checkpoint recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Checkpoint Therapeutics. Macroaxis does not own or have any residual interests in Checkpoint Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Checkpoint Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Checkpoint Therapeutics Trading Alerts and Improvement Suggestions
| Checkpoint Therapeutics is way too risky over 90 days horizon | |
| Checkpoint Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 103 K. Net Loss for the year was (51.85 M) with loss before overhead, payroll, taxes, and interest of (27.59 M). | |
| Checkpoint Therapeutics currently holds about 30.89 M in cash with (47.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Checkpoint Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Fortress Biotech, Inc. of 146341 shares of Checkpoint Therapeutics subject to Rule 16b-3 |
Checkpoint Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Checkpoint analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Checkpoint analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Checkpoint Therapeutics Returns Distribution Density
The distribution of Checkpoint Therapeutics' historical returns is an attempt to chart the uncertainty of Checkpoint Therapeutics' future price movements. The chart of the probability distribution of Checkpoint Therapeutics daily returns describes the distribution of returns around its average expected value. We use Checkpoint Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Checkpoint Therapeutics returns is essential to provide solid investment advice for Checkpoint Therapeutics.
| Mean Return | 0.24 | Value At Risk | -6.8 | Potential Upside | 10.94 | Standard Deviation | 9.08 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Checkpoint Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Checkpoint Stock Institutional Investors
The Checkpoint Therapeutics' institutional investors refer to entities that pool money to purchase Checkpoint Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Wealth Enhancement Advisory Services, Llc | 2024-12-31 | 130 K | Omers Administration Corp | 2024-12-31 | 116.9 K | Bank Of America Corp | 2024-12-31 | 90 K | Royal Bank Of Canada | 2024-12-31 | 89.9 K | Legacy Wealth Asset Management, Llc | 2024-12-31 | 85 K | Two Sigma Investments Llc | 2024-12-31 | 73 K | Northern Trust Corp | 2024-12-31 | 72.6 K | Squarepoint Ops Llc | 2024-12-31 | 71.9 K | Ubs Group Ag | 2024-12-31 | 71.8 K | Armistice Capital, Llc | 2024-12-31 | 4.5 M | Vanguard Group Inc | 2024-12-31 | 1.9 M |
Checkpoint Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 14.7M | 14.0M | (42.7M) | (7.1M) | (6.4M) | (6.1M) | |
| Free Cash Flow | (16.6M) | (26.3M) | (57.6M) | (47.6M) | (42.8M) | (40.7M) | |
| Other Non Cash Items | 5.5M | 7.6M | 6.8M | 4.2M | 3.7M | 4.3M | |
| Net Income | (23.1M) | (56.7M) | (62.6M) | (51.8M) | (46.7M) | (49.0M) | |
| End Period Cash Flow | 40.8M | 54.7M | 12.1M | 4.9M | 4.4M | 4.2M | |
| Change To Netincome | 2.8M | 3.9M | 3.7M | 10.8M | 9.7M | 5.6M | |
| Change Receivables | (1.2M) | 1.5M | 6K | 3K | 3.5K | 3.3K |
Checkpoint Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Checkpoint Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Checkpoint Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Checkpoint stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.0053 | |
β | Beta against Dow Jones | -2.13 | |
σ | Overall volatility | 9.33 | |
Ir | Information ratio | 0.04 |
Checkpoint Therapeutics Volatility Alert
Checkpoint Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Checkpoint Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Checkpoint Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Checkpoint Therapeutics Fundamentals Vs Peers
Comparing Checkpoint Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Checkpoint Therapeutics' direct or indirect competition across all of the common fundamentals between Checkpoint Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Checkpoint Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Checkpoint Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Checkpoint Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Checkpoint Therapeutics to competition |
| Fundamentals | Checkpoint Therapeutics | Peer Average |
| Return On Equity | -12.2 | -0.31 |
| Return On Asset | -6.34 | -0.14 |
| Operating Margin | (798.17) % | (5.51) % |
| Current Valuation | 214.68 M | 16.62 B |
| Shares Outstanding | 54.56 M | 571.82 M |
| Shares Owned By Insiders | 19.83 % | 10.09 % |
| Shares Owned By Institutions | 17.60 % | 39.21 % |
| Number Of Shares Shorted | 7.49 M | 4.71 M |
| Price To Earning | (7.60) X | 28.72 X |
| Price To Book | 8.56 X | 9.51 X |
| Price To Sales | 4,668 X | 11.42 X |
| Revenue | 103 K | 9.43 B |
| Gross Profit | (27.59 M) | 27.38 B |
| EBITDA | (52.15 M) | 3.9 B |
| Net Income | (51.85 M) | 570.98 M |
| Cash And Equivalents | 30.89 M | 2.7 B |
| Cash Per Share | 0.33 X | 5.01 X |
| Total Debt | 18.43 M | 5.32 B |
| Debt To Equity | 0.1 % | 48.70 % |
| Current Ratio | 1.30 X | 2.16 X |
| Book Value Per Share | (0.28) X | 1.93 K |
| Cash Flow From Operations | (47.59 M) | 971.22 M |
| Short Ratio | 9.81 X | 4.00 X |
| Earnings Per Share | (1.83) X | 3.12 X |
| Target Price | 4.33 | |
| Number Of Employees | 23 | 18.84 K |
| Beta | 1.42 | -0.15 |
| Market Capitalization | 219.39 M | 19.03 B |
| Total Asset | 5.38 M | 29.47 B |
| Retained Earnings | (314.33 M) | 9.33 B |
| Working Capital | (13.05 M) | 1.48 B |
| Current Asset | 46.85 M | 9.34 B |
| Current Liabilities | 2.89 M | 7.9 B |
Note: Acquisition by Fortress Biotech, Inc. of 146341 shares of Checkpoint Therapeutics subject to Rule 16b-3 [view details]
Checkpoint Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Checkpoint . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Checkpoint Therapeutics Buy or Sell Advice
When is the right time to buy or sell Checkpoint Therapeutics? Buying financial instruments such as Checkpoint Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Checkpoint Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.